Published on December 11, 2020

North Coast Healthcare Collaborative Provides Various Treatments for COVID-19

(December 11, 2020, Sandusky) – As the COVID-19 pandemic has evolved, so have the treatments offered by affiliated providers of the North Coast Healthcare Collaborative. It is each organization’s goal to provide the best care possible for their patients during this time.

The pandemic is an ever-evolving situation, and as time has gone on, providers in the region have implemented more effective treatments for patients with COVID-19. Many treatments and therapies are available to treat COVID-19, but every scenario and patient is different and unique. There are different stages within the life-cycle of the virus where the various treatment options are appropriate.

“Monoclonal antibodies are lab-created synthetic antibodies intended for use in COVID-19 positive patients early on in the disease before they are sick enough for hospitalization,” said Dr. Scott Campbell, Firelands Regional Health System’s Chief Medical Officer. “This is specifically targeted at patients who are at the highest risk to go on to have a bad outcome secondary to coronavirus. Monoclonal antibodies are utilized on an outpatient basis only, and are therefore not indicated for admitted patients. They are supplied to our hospitals by allotment from the State, just like remdesivir was in the beginning.” According to the U.S. Food and Drug Administration, “monoclonal antibodies mimic the immune system’s ability to fight off harmful pathogens, such as viruses.”

Considering that monoclonal antibodies are used as early treatments, there are different treatments used for patients that have been admitted for acute care. Magruder Hospital President and CEO, Nick Marsico, said, “dexamethasone and remdesivir are used as inpatient therapies when the patient qualifies, and we have seen success when ordering these treatments for our patients.” Both dexamethasone and remdesivir have proven to decrease viral loads as well as the length of the illness.

All three treatments, including monoclonal antibodies, dexamethasone, and remdesivir, are used for patient care by all four area healthcare providers. “They generally are not all used together in combination at the same time in treating COVID-19, but could all be administered progressively to the same patient over the course of treating a patient for COVID-19,” said Fisher Titus’ President and CEO, Dr. Brent Burkey. “The determination of what is used is based on an individual patient’s demographics, risk factors, and clinical state of illness, in addition to the overall timing in the course of illness related to COVID-19.” All treatments require learning, training, and processes to care for patients in the region with the highest level of safety in mind. That means if a new treatment becomes available, NCHC has to plan and prepare their associates accordingly, taking the time to consider new opportunities while maintaining patient care each and every day.


About the North Coast Healthcare Collaborative

The North Coast Healthcare Collaborative consists of The Bellevue Hospital, Firelands Regional Health System, Fisher-Titus Medical Center, and Magruder Hospital. These locally-owned, independent hospitals have chosen a path of collaboration over competition in order to improve healthcare in the region and achieve long-term financial stability.

Media Inquiries

During regular business hours, please contact the Marketing Department.

Contact Us